Qiagen N.V. (QGEN)

$43.06 +0.74 (1.75%)
Market Cap 9.41B
Revenue (ttm) 1.98B
Net Income (ttm) 83.59M
EPS (ttm) N/A
PE Ratio 18.94
Forward PE 18.17
Profit Margin 4.23%
Debt to Equity Ratio 0.39
Volume 1,213,330
Avg Vol 1,357,246
Day's Range N/A - N/A
Shares Out 222.29M
Stochastic %K 79%
Beta 0.62
Analysts Strong Sell
Price Target $49.47

Latest News on QGEN

QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025

Apr 22, 2025, 4:05 PM EDT - 2 days ago

QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025

QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation

Apr 15, 2025, 1:30 AM EDT - 10 days ago

QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation

QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast

Apr 8, 2025, 11:22 AM EDT - 16 days ago

QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast

QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook

Apr 6, 2025, 2:28 PM EDT - 18 days ago

QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook

QIAGEN Launches QIAprep&amp Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts

Apr 1, 2025, 1:30 AM EDT - 24 days ago

QIAGEN Launches QIAprep&amp Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts

QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results

Mar 31, 2025, 6:00 AM EDT - 24 days ago

QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results

QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio

Mar 6, 2025, 1:00 AM EST - 7 weeks ago

QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio

QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing

Mar 3, 2025, 1:00 AM EST - 7 weeks ago

QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing

Qiagen N.V.: Some Clarity Needed Before Buying The Dip

Feb 25, 2025, 4:39 PM EST - 2 months ago

Qiagen N.V.: Some Clarity Needed Before Buying The Dip

QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region

Feb 13, 2025, 4:05 PM EST - 2 months ago

QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region

Qiagen N.V. (QGEN) Q4 2024 Earnings Call Transcript

Feb 6, 2025, 4:49 PM EST - 2 months ago

Qiagen N.V. (QGEN) Q4 2024 Earnings Call Transcript

QIAGEN delivers solid Q4 2024 growth ahead of outlook

Feb 5, 2025, 4:05 PM EST - 2 months ago

QIAGEN delivers solid Q4 2024 growth ahead of outlook

QIAGEN receives positive court decision reaffirming an important QuantiFERON-TB patent

Feb 4, 2025, 4:05 PM EST - 2 months ago

QIAGEN receives positive court decision reaffirming an important QuantiFERON-TB patent

QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million

Jan 16, 2025, 4:05 PM EST - 3 months ago

QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million

QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast

Jan 15, 2025, 8:13 AM EST - 3 months ago

QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast

QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase

Jan 12, 2025, 1:05 PM EST - 3 months ago

QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase

QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples

Jan 10, 2025, 1:30 AM EST - 3 months ago

QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples

QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care

Jan 9, 2025, 4:05 PM EST - 3 months ago

QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care

QIAGEN Supports UK Initiative to Sequence Genomes of 100,000 Newborns With Expert-Curated Genomic Content

Jan 7, 2025, 4:05 PM EST - 3 months ago

QIAGEN Supports UK Initiative to Sequence Genomes of 100,000 Newborns With Expert-Curated Genomic Content

QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data

Dec 12, 2024, 4:05 PM EST - 4 months ago

QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data

QIAGEN Reaches Milestone With Over 1,000 Placements of EZ2 Connect Sample Preparation Instrument, Driving Laboratory Automation

Dec 5, 2024, 4:05 PM EST - 5 months ago

QIAGEN Reaches Milestone With Over 1,000 Placements of EZ2 Connect Sample Preparation Instrument, Driving Laboratory Automation

QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing

Nov 28, 2024, 6:00 AM EST - 5 months ago

QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing

QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis

Nov 27, 2024, 4:05 PM EST - 5 months ago

QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis

Qiagen N.V. (QGEN) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 3:58 PM EST - 6 months ago

Qiagen N.V. (QGEN) Q3 2024 Earnings Call Transcript

Diagnostics firm Qiagen reports rise in third-quarter revenue

Nov 6, 2024, 4:35 PM EST - 6 months ago

Diagnostics firm Qiagen reports rise in third-quarter revenue

QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics

Nov 4, 2024, 1:30 AM EST - 6 months ago

QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics

QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment

Oct 29, 2024, 2:30 AM EDT - 6 months ago

QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment

QIAGEN expands automated liquid biopsy portfolio to enhance oncology, prenatal care and organ transplant applications

Oct 10, 2024, 4:05 PM EDT - 7 months ago

QIAGEN expands automated liquid biopsy portfolio to enhance oncology, prenatal care and organ transplant applications

QIAGEN N.V. to release results for Q3 2024 and hold webcast

Oct 10, 2024, 7:41 AM EDT - 7 months ago

QIAGEN N.V. to release results for Q3 2024 and hold webcast

Global TB Summit 2024: QIAGEN leads the charge as tuberculosis reemerges as a leading infectious killer

Oct 7, 2024, 4:05 PM EDT - 7 months ago

Global TB Summit 2024: QIAGEN leads the charge as tuberculosis reemerges as a leading infectious killer

QIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncology

Sep 30, 2024, 4:05 PM EDT - 7 months ago

QIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncology

QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays

Sep 26, 2024, 4:05 PM EDT - 7 months ago

QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays

PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samples

Sep 25, 2024, 4:05 PM EDT - 7 months ago

PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samples

QIAGEN and Bode Technology partner to advance use of GEDmatch PRO forensic genetic genealogy database

Sep 23, 2024, 4:05 PM EDT - 7 months ago

QIAGEN and Bode Technology partner to advance use of GEDmatch PRO forensic genetic genealogy database

QIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platform

Sep 18, 2024, 4:05 PM EDT - 7 months ago

QIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platform

QIAGEN and Bio-Manguinhos/Fiocruz collaborate to enhance malaria and dengue detection in Brazil's national screening programs

Sep 12, 2024, 4:05 PM EDT - 8 months ago

QIAGEN and Bio-Manguinhos/Fiocruz collaborate to enhance malaria and dengue detection in Brazil's national screening programs

QIAGEN and Lilly collaborate to support development of a QIAstat-Dx IVD panel that identifies patients at risk for developing Alzheimer's disease

Sep 4, 2024, 4:05 PM EDT - 8 months ago

QIAGEN and Lilly collaborate to support development of a QIAstat-Dx IVD panel that identifies patients at risk for developing Alzheimer's disease

QIAGEN N.V. announces conversion price of new net share settled convertible bonds

Sep 3, 2024, 5:05 PM EDT - 8 months ago

QIAGEN N.V. announces conversion price of new net share settled convertible bonds

QIAGEN N.V. announces successful placement of new net share settled convertible bonds

Sep 3, 2024, 11:00 AM EDT - 8 months ago

QIAGEN N.V. announces successful placement of new net share settled convertible bonds

QIAGEN N.V. launches non-US offering of net share settled convertible bonds

Sep 3, 2024, 2:36 AM EDT - 8 months ago

QIAGEN N.V. launches non-US offering of net share settled convertible bonds

QIAGEN expands QIAstat-Dx into precision medicine through partnership for companion diagnostics in chronic diseases

Aug 28, 2024, 4:05 PM EDT - 8 months ago

QIAGEN expands QIAstat-Dx into precision medicine through partnership for companion diagnostics in chronic diseases

Qiagen N.V. (QGEN) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 3:04 PM EDT - 9 months ago

Qiagen N.V. (QGEN) Q2 2024 Earnings Call Transcript

QIAGEN delivers solid performance and exceeds outlook for Q2 2024

Jul 31, 2024, 4:06 PM EDT - 9 months ago

QIAGEN delivers solid performance and exceeds outlook for Q2 2024

QIAGEN N.V. to release results for Q2 2024 and hold webcast

Jul 2, 2024, 9:29 AM EDT - 10 months ago

QIAGEN N.V. to release results for Q2 2024 and hold webcast

QIAGEN welcomes new U.S. guidelines for use of QuantiFERON-TB Gold Plus in detecting tuberculosis infections in children

Jun 27, 2024, 4:05 PM EDT - 10 months ago

QIAGEN welcomes new U.S. guidelines for use of QuantiFERON-TB Gold Plus in detecting tuberculosis infections in children

QIAGEN announces 2028 strategy for solid profitable growth

Jun 17, 2024, 7:30 AM EDT - 11 months ago

QIAGEN announces 2028 strategy for solid profitable growth

QIAGEN's software QCI Interpret accelerates clinical reporting turnaround time for high throughput NGS testing labs

Jun 13, 2024, 4:05 PM EDT - 11 months ago

QIAGEN's software QCI Interpret accelerates clinical reporting turnaround time for high throughput NGS testing labs

QIAGEN publishes 2023 sustainability report, highlighting progress on ESG goals and commitment to sustainable growth

Jun 12, 2024, 4:05 PM EDT - 11 months ago

QIAGEN publishes 2023 sustainability report, highlighting progress on ESG goals and commitment to sustainable growth

QIAGEN launches new QIAcuity digital PCR assays for microbial applications, enhancing infectious disease research and surveillance

Jun 11, 2024, 4:05 PM EDT - 11 months ago

QIAGEN launches new QIAcuity digital PCR assays for microbial applications, enhancing infectious disease research and surveillance

QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition period

Jun 6, 2024, 4:05 PM EDT - 11 months ago

QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition period